+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID06928753

Evaluating Real-World Effectiveness, Safety, and Immune Response of IXCHIQ and VIMKUNYA Vaccines Against Chikungunya Virus During Epidemics in Runion Island and French Guiana

Led by Centre Hospitalier Universitaire de la Réunion · Updated on 2026-09-28

1505

Participants Needed

2

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying chikungunya virus infection by evaluating the real-world effectiveness, safety, and immune response of two vaccines, IXCHIQ and VIMKUNYA, during an epidemic period in Runion Island and French Guiana. This ambispective Phase 4 study aims to provide insights into vaccine performance as defined by the French National Authority for Health HAS. Participants will be assigned to either a vaccinated group receiving IXCHIQ or VIMKUNYA vaccines or a non-vaccinated group. The study involves both retrospective and prospective components, including adults eligible for vaccination according to HAS criteria. All participants must consent and have French social security coverage. During the study, researchers will assess vaccine effectiveness at 6 months. Participants will be monitored for safety and immune response after vaccination. Data collection includes tracking vaccination status and health outcomes over the study period, which runs from April 2025 to December 2027.

CONDITIONS

Brief Title

Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French Guiana

Research Team

P

Patrick GERARDIN, MD

F

Florence LEFEBVRE D'HELLENCOURT

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here